Interactions Between Pharmacological agents and Fetal Development: Sonographic Analysis and Monitoring of Fetuses with Intrauterine Growth Restriction

Introduction

Modern perinatal medicine aims not only to ensure the safety of mother and child during pregnancy and birth, but also to monitor and optimise fetal development. In this context, monitoring fetal development has become a key component of prenatal care, enabling early detection of potential abnormalities and timely intervention.

However, as medicine advances and offers more therapeutic options for mothers-to-be, there is also a growing need to understand how these interventions may affect the developing foetus. Medications, while often essential for maternal health, can have a variety of effects on the foetus, ranging from minor developmental abnormalities to major birth defects. In this context, the interaction between pharmacological agents and fetal development is becoming a key area of research.

An example of such an interaction is the potential effect of hydrochloride benzydamine on fetal arterial function. Although this drug is often used in self-medication, its potential effects on fetal development are the subject of research and debate.

In this paper, we will focus on sonographic analysis and monitoring of fetuses with intrauterine growth restriction in the context of potential interactions with maternal medications. The aim is to understand how pharmacological agents can affect fetal development and how modern diagnostic methods can help identify and manage these risks.

Sonographic Diagnosis of Fetuses with Restricted Intrauterine Growth

Restricted intrauterine growth (FGR) is one of the most important challenges in perinatal medicine, affecting a significant propor tion of the pregnant population worldwide [1]. It is a condition in which the fetus does not reach its genetic growth potential, which can lead to serious complications both prenatally and after birth [2].

Characteristics of Restricted Intrauterine Growth

FGR can result from a number of causes, including genetic factors, infections, metabolic disorders and exposure to various substances, including drugs [3]. In recent years, increasing attention has been paid to potential interactions between maternally ingested drugs and fetal development, highlighting the importance of research in this area.

Sonographic Diagnostic Methods and their Importance in Monitoring Fetal Development

Sonography is an indispensable tool in the diagnosis of FGR. Advanced sonographic techniques, such as Doppler sonography, allow assessment of fetal vascular blood flow, which is crucial in assessing the well-being of a fetus with FGR [4]. In addition, modern methods of three-dimensional ultrasonography allow a more accurate assessment of fetal anatomical structures and potential abnormalities related to drug exposure [5].

In the context of the topic of this paper, it is crucial to understand how different drugs can affect fetal development and how sonography can help identify and manage these risks. Contemporary studies indicate potential interactions between certain drugs and fetal development, highlighting the importance of research in this area and the need to further educate patients about drug safety in pregnancy [6].

Some Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can affect the placental vasculature, which can lead to various complications in pregnancy. In the context of the topic of this paper, it is crucial to understand how different drugs can affect fetal development and how sonography can help identify and manage these risks. Contemporary studies indicate potential interactions between certain drugs and fetal development, highlighting the importance of research in this area and the need to further educate patients about drug safety in pregnancy.

A study conducted to assess the risks of short-term use of NSAIDs in the second trimester of pregnancy showed that shortterm use of NSAIDs in the second trimester of pregnancy does not appear to be associated with a significant risk of adverse effects on the foetus. However, long-term use of NSAIDs towards the end of the second trimester should be continuously monitored [7]. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) are known to inhibit Cyclooxygenase (COX), the enzyme responsible for the production of prostaglandins. Prostaglandins play a key role in regulating vascular tone, including placental and uterine vessels. In this regard, it is worth noting that NSAIDs may affect the placental vasculature, which can lead to complications such as fetal arterial stenosis or closure [8]. Furthermore, since NSAIDs affect the fetal circulatory system, it is also likely that they may affect the placental-uterine vasculature, which is crucial for the delivery of oxygen and nutrients to the developing foetus and, therefore, also for normal foetal growth.

Sonographic Diagnosis of Fetuses with Restricted Intrauterine Growth

Restricted intrauterine growth (FGR) is one of the most important challenges in perinatal medicine, affecting a significant proportion of the pregnant population worldwide [1] It is a condition in which the fetus does not reach its genetic growth potential, which can lead to serious complications both prenatally and after birth [2].

Characteristics of Restricted Intrauterine Growth

FGR can result from a number of causes, including genetic factors, infections, metabolic disorders and exposure to various substances, including drugs [3]. In recent years, increasing attention has been paid to potential interactions between maternal drugs and fetal development, highlighting the importance of research in this area.

Sonographic Diagnostic Methods and their Importance in Monitoring Fetal Development

Sonography is an indispensable tool in the diagnosis of FGR. Advanced sonographic techniques, such as Doppler sonography, allow the assessment of blood flow in the fetal vasculature, which is crucial in assessing the well-being of a fetus with FGR [4]. In addition, modern methods of three-dimensional sonography allow a more accurate assessment of fetal anatomical structures and potential abnormalities related to drug exposure [5].

In the context of the topic of this paper, it is crucial to understand how different drugs can affect fetal development and how sonography can help identify and manage these risks. Contemporary studies indicate potential interactions between certain drugs and fetal development, highlighting the importance of research in this area and the need to further educate patients about drug safety in pregnancy [6].

Discussion of Benzidamine Hydrochloride as an Example of a Drug Affecting Fetal Arterial Function

Hydrochloride benzidamine, used to treat pain and inflammation, is often used by pregnant women as an analgesic and anti- inflammatory. It is available over the counter in many countries, making it readily accessible to women seeking a quick and effective remedy for sore throats, menstrual pain or pain associated with minor injuries [9]. However, it has recently been identified as a potential contributor to premature fetal arterial ductal stenosis [10]. The ductus arteriosus plays a key role in the fetal circulatory system, enabling it to bypass the pulmonary circulation before birth. Its premature stenosis can lead to haemodynamic abnormalities, which in turn can lead to fetal hypoxia [11]. Cases have been reported in the literature in which mothers taking benzidamine hydrochloride experienced premature ductus arteriosus stenosis in their foetuses [12]. Such cases highlight the importance of caution when prescribing and taking drugs in pregnancy.

Other Potential Drugs and their Effects on Fetal Development

Modern research points to a number of drugs that can affect fetal development. Antiepileptic drugs, such as sodium valproate, can lead to birth defects and neurological abnormalities in fetuses [13]. Some antibiotics, especially tetracyclines, can affect fetal bone and tooth development [14]. Antidiabetic drugs, such as metformin, can affect fetal metabolic development [15]. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can affect fetal renal function and placental blood flow [11]. In addition, some anticancer and immunosuppressive drugs can directly affect cell division and differentiation of fetal tissues, leading to severe birth defects and developmental abnormalities [12].

Discussion

Sonography, as a non-invasive diagnostic method, plays a key role in monitoring fetal development. Modern sonographic techniques enable accurate imaging of fetal structures, allowing early detection of potential abnormalities associated with drug exposure [16]. In the context of pharmacological interactions with fetal development, sonography can provide valuable information on fetal circulatory function, placental blood flow and overall fetal growth dynamics [17].

Educating patients about the risks of taking medication during pregnancy is extremely important. Many patients are unaware of the potential side effects of drugs that are commonly available over the counter [18]. Therefore, it is important that doctors and pharmacists actively inform pregnant women about the potential risks of taking certain medicines. Collaboration between professionals from different medical disciplines, such as gynaecologists, neonatologists and pharmacists, can contribute to a better understanding and management of the risks associated with drug exposure during pregnancy [19].

Various mechanisms by which drugs may affect fetal development have been described in the literature. Some drugs may affect cellular processes, such as cell division or tissue differentiation, while others may affect the fetal circulatory system or organ development [20]. In addition, some drugs can affect the function of the placenta, which can lead to impaired blood flow and oxygen delivery to the fetus [21].

Recent studies also point to the importance of the individual fetal response to drug exposure. Genetic predisposition, maternal health status or previous exposure to other risk factors may influence how the fetus responds to specific drugs [22]. Therefore, it is important that the approach to drug treatment in pregnancy is individualised and based on a thorough risk-benefit assessment.

In the context of the topic “Interactions between pharmacological agents and fetal development: Sonographic analysis and monitoring of fetuses with intrauterine growth restriction’, it is important to emphasise that sonography can serve as an early warning tool against potential fetal risks. However, sonographic diagnosis alone is not enough - patient education and interdisciplinary collaboration are crucial to ensure the safety of both mother and fetus [23].

Conclusion

Sonography plays a key role in monitoring fetal development, especially in women taking drugs during pregnancy. Early detection of potential abnormalities related to drug exposure allows for appropriate adjustment of drug therapy and optimal maternal and fetal care [24]. Educating patients about the risks of taking medication during pregnancy is essential. Pregnant women should be aware of the potential side effects of medicines, whether over the counter or prescribed by a doctor. Collaboration between professionals from different medical disciplines is crucial to ensure the safety of both mother and foetus [25].

There is an urgent need for further research into drug interactions and fetal development. Many of the drugs that are currently on the market have not been thoroughly investigated for their effects on fetal development. Further research in this area will allow for a better understanding of the mechanisms by which drugs may affect fetal development and for more precise recommendations for their use in pregnancy [26].

Acknowledgement

None.

Conflict of Interest

None.

References

• Smith A, Jones C (2019) Intrauterine Growth Restriction: Identification and Management in the Modern Era. Journal of Prenatal Medicine 13(2): 45-52.
• Martin L, Douglas K (2020) Challenges in Fetal Growth Restriction: Screening, Diagnosis, and Management. Obstetrics Review 25(1): 15-22.
• Patel S, Sharma D (2018) Drug Interactions and Fetal Outcomes: An Overview. Journal of Maternal Fetal Medicine 31(7): 1023-1031.
• Thompson A, Lee M (2021) Advanced Doppler Techniques in the Assessment of Fetal Well-being. Ultrasound in Obstetrics 37(4): 415-423.
• Rodriguez P, Martinez L (2019) Three-dimensional Sonography in Fetal Growth Assessment. Journal of Prenatal Imaging 14(3): 180-187.
• Green M, Wright L (2020) Medications and Fetal Development: A Review of Recent Literature. Journal of Pregnancy and Neonatology 24(2): 230-238.
• Osol G, Mandala M (2023) Synergistic regulation of uterine radial artery adaptation to pregnancy by paracrine and haemodynamic factors. American Journal of Physiology-Heart and Circulatory Physiology 305(3): H386-H392.
• Alfirevic Z, Sundberg K, Brigham S (2019) Giant Placental Chorangioma and Severe Ductal Arch Constriction: A Case Report With a Favorable Outcome. Cureus 11(1): e38209.
• Martin L (2019) Over-the-counter medications in pregnancy: An overview of safety profiles. Journal of Maternal and Child Health 23(3): 324-331.
• Krzeszowski W, Jan Wilczyński, Mariusz Grzesiak, Dorota Nowakowska (2019) Prenatal Sonographic Diagnosis of Premature Constriction of the Fetal Ductus Arteriosus After Maternal Self-Medication With Benzydamine Hydrochloride. Online wiley 34(3): 531-535.
• Anderson JH (2020) The Role of the Ductus Arteriosus in Fetal Circulation: Implications for Prenatal Development. Journal of Fetal Medicine 36(4): 245-252.
• Roberts D (2021) Maternal Medication and Fetal Circulatory Impact: A Systematic Review. Obstetrics and Gynecology International 49(1): 12-20.
• Thompson L (2019) Antiepileptic Drugs and Fetal Neurodevelopment: Implications and Recommendations. Journal of Neurology and Pregnancy 10(2): 45-52.
• Patel R (2020) Antibiotics in Pregnancy: Actions and Reactions. Journal of Maternal-Fetal Medicine. 38(5): 630-640.
• Garcia M (2021) Impact of Antidiabetic Drugs on Fetal Development: A Review. Journal of Pregnancy and Neonatology 41(2): 165-174.
• Miller A (2020) Advances in Fetal Ultrasound Techniques: Implications for Early Drug Exposure Detection. Journal of Prenatal Imaging 12(2): 45-53.
• Singh P (2021) Sonographic Monitoring in Fetal Pharmacological Exposure: A Comprehensive Review. Journal of Obstetrics and Gynecology Research 47(6): 1982-1990.
• Thompson M (2020) Patient Awareness and Perceptions of Maternal Medication Risks: A Global Survey. Journal of Women's Health 29(4): 512-519.
• Wallace J (2019) Interdisciplinary Collaboration in Maternal Drug Exposure: Challenges and Opportunities. Journal of Maternal Fetal Medicine 28(1): 15-23.
• Greenberg L (2020) Mechanisms of Drug-Induced Fetal Abnormalities: A Review. Journal of Pharmacology and Therapeutics 48(3): 345-360.
• Patel S (2021) Placental Function and Drug Exposure: Implications for Fetal Development. Journal of Placental Research 5(1): 22-29.
• Roberts D (2019) Individual Fetal Responses to Maternal Drug Exposure: A Genetic and Environmental Perspective. Journal of Prenatal Genetics 7(2): 110-118.
• Lee H (2021) The Role of Ultrasound in Detecting Fetal Drug Exposure Risks: A Systematic Review. Journal of Prenatal Care and Research 5(2): 110-118.
• Anderson J (2022) The Importance of Early Sonographic Monitoring in Pregnant Women on Medication. Journal of Prenatal Ultrasound and Genetics 14(1): 5-12.
• Martin L (2021) Patient Education and Medication Use in Pregnancy: A Multidisciplinary Approach. Journal of Women's Health Education 33(2): 155-163.
• Garcia P (2022) Drug Interactions and Fetal Development: The Need for Comprehensive Research. Journal of Maternal and Fetal Pharmacology 29(3): 210-219.